Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, and Augmentin ®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, in Healthy Volunteers Under Fasting Conditions

Condition:   Healthy Adults Interventions:   Drug: Clavamox;   Drug: Augmentin® Sponsors:   Pharmtechnology LLC;   ClinPharmInvest CRO Active, not recruiting

Source: ClinicalTrials.gov - August 6, 2018 Category: Research Source Type: clinical trials